此前,赛诺菲已对外宣布,将耗资95亿美元收购Blueprint Medicines 公司,7月18日,赛诺菲(Sanofi)对外宣布,其已完成了对Blueprint Medicines 公司的收购。此次收购旨在拓宽罕见病治疗管线。Blueprint Medicines有一款已在美国和欧盟获批上市的药物Ayvakit/Ayvakyt(阿伐替尼,avapritinib),该产品是目前唯一获批用于治疗...
Source Link此前,赛诺菲已对外宣布,将耗资95亿美元收购Blueprint Medicines 公司,7月18日,赛诺菲(Sanofi)对外宣布,其已完成了对Blueprint Medicines 公司的收购。此次收购旨在拓宽罕见病治疗管线。Blueprint Medicines有一款已在美国和欧盟获批上市的药物Ayvakit/Ayvakyt(阿伐替尼,avapritinib),该产品是目前唯一获批用于治疗...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.